Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F21%3A00552788" target="_blank" >RIV/68378041:_____/21:00552788 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11140/21:10434869 RIV/00216208:11110/21:10434869
Výsledek na webu
<a href="https://www.mdpi.com/2072-6643/13/11/4164" target="_blank" >https://www.mdpi.com/2072-6643/13/11/4164</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/nu13114164" target="_blank" >10.3390/nu13114164</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Popis výsledku v původním jazyce
Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes, (2) pathway SNPs present in enzymes' coding regions and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84-1.27 and OR: 1.08, 95% CI: 0.86-1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.
Název v anglickém jazyce
Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study
Popis výsledku anglicky
Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes, (2) pathway SNPs present in enzymes' coding regions and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84-1.27 and OR: 1.08, 95% CI: 0.86-1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
10603 - Genetics and heredity (medical genetics to be 3)
Návaznosti výsledku
Projekt
<a href="/cs/project/NU21-07-00247" target="_blank" >NU21-07-00247: Využití konceptu tekuté biopsie pro charakterizaci mikroRNA a onkogenní KRAS mutace pro stanovení včasné diagnózy a zhodnocení rizika vzniku karcinomu pankreatu.</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Nutrients
ISSN
2072-6643
e-ISSN
2072-6643
Svazek periodika
13
Číslo periodika v rámci svazku
11
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
21
Strana od-do
4164
Kód UT WoS článku
000732628500001
EID výsledku v databázi Scopus
2-s2.0-85119379732